CJC-1295 Without DAC (Mod GRF 1-29)

CJC-1295 without DAC (Mod GRF 1-29) is a modified GHRH(1-29) analog with four amino acid substitutions for enhanced DPP-IV resistance. Produces pulsatile GH release through GHRH receptor activation.

CJC-1295 without DAC, widely known as Modified GRF(1-29) or Mod GRF 1-29, is a synthetic analog of the biologically active N-terminal 29-amino acid fragment of human growth hormone-releasing hormone (GHRH 1-44). The native GHRH(1-29) sequence is rapidly degraded in vivo primarily by dipeptidyl peptidase-IV (DPP-IV), which cleaves the Tyr1-Ala2 N-terminal dipeptide, and by non-specific aminopeptidases. To overcome this enzymatic vulnerability, four strategic amino acid substitutions were introduced: D-Ala at position 2 (DPP-IV resistance), Gln at position 8 (asparagine deamidation prevention), Ala at position 15 (oxidation resistance), and Leu at position 27 (enhanced receptor binding). These modifications collectively extend the metabolic stability of the peptide while maintaining full agonist activity at the GHRH receptor.

CJC-1295 without DAC activates the GHRH receptor (GHRHR), a class B G-protein coupled receptor (GPCR) expressed on anterior pituitary somatotroph cells. Receptor activation stimulates adenylyl cyclase, increasing intracellular cAMP, which activates protein kinase A (PKA) and CREB transcription factor phosphorylation. This signaling cascade drives both GH gene transcription and GH granule exocytosis. The absence of the Drug Affinity Complex (DAC) means this peptide produces shorter-duration, pulsatile GH elevation patterns that more closely resemble endogenous GHRH signaling — a critical distinction for research studying physiological GH pulse dynamics, somatostatin feedback mechanisms, and circadian GH rhythms.

Published research has established that CJC-1295 without DAC demonstrates synergistic GH release when co-administered with ghrelin receptor agonists (GHRPs) in research models. This synergy arises because GHRHR and GHS-R1a (ghrelin receptor) utilize complementary intracellular signaling pathways — cAMP/PKA and IP3/calcium respectively — that converge on GH secretory machinery within individual somatotroph cells. This mechanistic synergy is the scientific basis for the widely studied CJC-1295/Ipamorelin combination in GH axis research.

Supplied as a lyophilized powder with ≥99% purity. Store at -20°C desiccated. For endocrinology and GH axis research only.

Product Specifications

Certificate of Analysis

Every batch ships with a Janoshik-verified COA covering HPLC purity, mass spectrometry confirmation, and batch traceability.

Shipping & Lead Times

• US warehouse: ships within 1–2 business days · estimated 3–5 day delivery
• HK warehouse: ships within 2–3 business days · estimated 7–14 day international delivery
• Carriers: DHL Express, FedEx International, UPS Worldwide
• Discreet outer packaging — no peptide branding visible
• Tracking number emailed on dispatch

Lost or Detained Packages

If your shipment is lost or detained by customs, we will reship once free of charge. Contact us with your order number.